Lisa A. Jackson is an internist and infectious disease epidemiologist who has spent the past 20 years conducting clinical and epidemiologic studies of vaccine safety and efficacy.
In addition to her role as a senior scientific investigator at Group Health Research Institute (GHRI), she is a research professor in the University of Washington (UW) Department of Epidemiology and an adjunct research professor in the UW Department of Medicine
Dr. Jackson is the principal investigator (PI) at Group Health of the Vaccine Safety Datalink Project sponsored by the Centers for Disease Control and Prevention. She is also PI of the Vaccine and Treatment Evaluation Unit hosted by GHRI, one of eight such facilities nationwide that are sponsored by the National Institutes of Health.
Dr. Jackson has authored more than 140 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Advisory Committee.
Dr. Jackson received her medical degree from the University of Virginia School of Medicine, Charlottesville, and her master of public health degree from the University of Washington School of Public Health and Community Medicine.
Vaccine safety; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM. Seasonal effectiveness of live attenuated and inactivated influenza vaccine. Pediatrics. 2016 Jan 5. pii: peds.2015-3279. [Epub ahead of print]. PubMed
Chen WH, Jackson LA, Edwards KM, Keitel WA, Hill H, Noah DL, Creech CB, Patel SM, Mangal B, Kotloff KL. Persistence of antibody to influenza A/H5N1 vaccine virus: impact of AS03 adjuvant. Clin Vaccine Immunol. 2015 Nov 11. pii: CVI.00475-15. [Epub ahead of print]. PubMed
Naleway AL, Crane B, Smith N, Daley MF, Donahue J, Gee J, Greene SK, Harrington T, Jackson LA, Klein NP, Tseng HF, Vellozzi C, Weintraub ES; Vaccine Safety Datalink. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2015 Nov 5. pii: S0264-410X(15)01417-6. doi: 10.1016/j.vaccine.2015.10.006. [Epub ahead of print].
Groom HC, Henninger ML, Smith N, Koppolu P, Cheetham TC, Glanz JM, Hambidge SJ, Jackson LA, Kharbanda EO, Klein NP, McCarthy NL, Nordin JD, Weintraub ES, Naleway AL. Influenza vaccination during pregnancy: influenza seasons 2002-2012, Vaccine Safety Datalink. Am J Prev Med. 2015 Oct 30. pii: S0749-3797(15)00505-X. doi: 10.1016/j.amepre.2015.08.017. [Epub ahead of print]. PubMed
GHRI’s Dr. Lisa Jackson is developing two clinical trials for malaria vaccines. She says Zika awareness may help prevent this far more prevalent killer.
Read it in News and Events.
Vaccine Treatment and Evaluation Unit tests real-world use to prepare for H7N9.
Read it in News and Events.
The Seattle Times, July 21, 2015